A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1

被引：0
|
作者：
Oh, D-Y. [1 ]
Chen, L-T. [2 ]
He, A. R. [3 ]
Okusaka, T. [4 ]
Qin, S. [5 ]
Chin, S. [6 ]
Rokutanda, N. [6 ]
Uchinda, H. [7 ]
Vogel, A. [8 ]
Valle, J. W. [9 ]
Kim, H. [7 ]
机构：
[1] Seoul Natl Univ Hosp, Internal Med, Seoul, South Korea
[2] Natl Inst Canc Res, Natl Hlth Res Inst, Tainan, Taiwan
[3] Georgetown Univ, Med Ctr, Div Hematol & Oncol, Washington, DC 20007 USA
[4] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan
[5] Peoples Liberat Army, Ctr Canc, Med Oncol, Nanjing, Jiangsu, Peoples R China
[6] AstraZeneca, Oncol, Gaithersburg, MD USA
[7] AstraZeneca KK, R&D, TA Div, Med Sci Dept Oncol, Osaka, Japan
[8] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany
[9] Univ Manchester, Christie NHS Fdn Trust, Inst Canc Sci, Med Oncol, Manchester, Lancs, England
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
831TiP
引用
收藏
页码：319 / 319
页数：1
相关论文
共 50 条
  • [41] Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC)
    Strumberg, Dirk
    Schultheis, Beate
    Ebert, Matthias Philip
    Kerkhoff, A.
    Hofheinz, Ralf Dieter
    Behringer, Dirk M.
    Schmidt, Wolfgang E.
    Goker, Erdem
    De Dosso, Sara
    Kneba, Michael
    Yalcin, Suayib
    Overkamp, Friedrich
    Schlegel, Frank
    Dommach, M.
    Rohrberg, Robert
    Steinmetz, Tilman
    Reuter, Dirk
    Bach, Ferdinand
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy in patients with stage III, locally advanced, unresectable NSCLC
    Laack, H. -E.
    Schulz, C.
    Wolff, T.
    Rueckert, A.
    Reck, M.
    Faehling, M.
    Fischer, J. R.
    de Wit, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 186 - 187
  • [43] PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy in patients with stage III, locally advanced, unresectable NSCLC
    de Wit, M.
    Laack, E.
    Schulz, C.
    Wolff, T.
    Rueckert, A.
    Reck, M.
    Faehling, M.
    Fischer, J.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 : S24 - S24
  • [44] DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED PHASE III TRIAL OF AFLIBERCEPT (A) PLUS GEMCITABINE (G) VERSUS PLACEBO (P) PLUS GEMCITABINE (G) IN PATIENTS WITH METASTATIC PANCREATIC CANCER: FINAL RESULTS
    Riess, H.
    Manges, R.
    Karasek, P.
    Humblet, Y.
    Barono, C.
    Santoro, A.
    Wojcik-Tomaszewska, J.
    Assadourian, S.
    Hatteville, L.
    Vincent, G.
    Philip, P.
    Rougier, P.
    ANNALS OF ONCOLOGY, 2010, 21 : 12 - 12
  • [45] Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliarytract cancer (KEYNOTE-966) : a randomised, double-blind, placebo-controlled, phase 3 trial
    Kelley, Robin Kate
    Ueno, Makoto
    Yoo, Changhoon
    Finn, Richard S.
    Furuse, Junji
    Ren, Zhenggang
    Yau, Thomas
    Klumpen, Heinz-Josef
    Chan, Stephen L.
    Ozaka, Masato
    Verslype, Chris
    Bouattour, Mohamed
    Park, Joon Oh
    Barajas, Olga
    Pelzer, Uwe
    Valle, Juan W.
    Yu, Li
    Malhotra, Usha
    Siegel, Abby B.
    Edeline, Julien
    Vogel, Arndt
    LANCET, 2023, 401 (10391): : 1853 - 1865
  • [46] A multicenter, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM).
    Kindler, HL
    Karrison, T
    Lu, C
    Gandara, DR
    Stevenson, J
    Krug, L
    Janne, P
    Guterz, TL
    Stadler, WM
    Vokes, EE
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 625S - 625S
  • [47] DURVALUMAB, IN COMBINATION WITH AND FOLLOWING CHEMORADIOTHERAPY, IN LOCALLY ADVANCED CERVICAL CANCER: RESULTS FROM THE PHASE 3 INTERNATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CALLA TRIAL
    Monk, Bradley
    Toita, Takafumi
    Wu, Xiaohua
    Carlos Limon, Juan
    Zhou, Qi
    Tarnawski, Rafal
    Mandai, Masaki
    Shapira-Frommer, Ronnie
    Mahantshetty, Umesh
    Estevez-Diz, Maria Del Pilar
    Ramirez Godinez, Francisco
    Varga, Szilvia
    Leiva Galvez, Manuel Humberto
    Lee, Jung-Yun
    Kreynina, Yulia
    Howells, Kathryn
    Wildsmith, Sophie
    Dry, Hannah
    Nunes, Ana
    Mayadev, Jyoti
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A2 - A3
  • [48] An International, Randomized, Double-blind, Placebo-controlled, Phase III Trial of Pregabalin Monotherapy in Treatment of Patients with Fibromyalgia
    Pauer, Lynne
    Winkelmann, Andreas
    Arsenault, Pierre
    Jespersen, Anders
    Whelan, Laurence
    Atkinson, Gary
    Leon, Teresa
    Zeiher, Bernhardt
    JOURNAL OF RHEUMATOLOGY, 2011, 38 (12) : 2643 - 2652
  • [49] AVAGAST: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE PHASE III STUDY OF CAPECITABINE/CISPLATIN + BEVACIZUMAB OR PLACEBO AS 1ST-LINE THERAPY IN PATIENTS WITH ADVANCED GASTRIC CANCER
    Ohtsu, A.
    Van Cutsem, E.
    Shah, M.
    Rha, S. Y.
    Sawaki, A.
    Park, S. R.
    Lim, H-Y
    Wu, J.
    Langer, B.
    Kang, Y-K
    ANNALS OF ONCOLOGY, 2010, 21 : 14 - 14
  • [50] PACIFIC: a double-blind, placebo-controlled Phase III study of durvalumab as consolidation therapy after chemoradiation in patients with locally advanced, unresectable NSCLC
    Schulz, C.
    Laack, E.
    Wolff, T.
    Rueckert, A.
    Reck, M.
    Faehling, M.
    Fischer, J. R.
    de Wit, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 270 - 270
12345